This review aims to provide a comprehensive overview of the current understanding of NUTM2A-AS1 in the development, progression, and metastasis of various cancers, including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma. This evidence concerns the gene NUTM2A and central nervous system cancer.